By Dr Adam Jacob Bryant

Book Chapters

Bryant A, 2021, 'Elotuzumab', in Resistance to Targeted Therapies in Multiple Myeloma, Springer Nature, pp. 73 - 82, http://dx.doi.org/10.1007/978-3-030-73440-4_6

Journal articles

Talaulikar D; Ng JY; Bryant A; Bosco A; Caterson HC; Giri P; Hissaria P; Harrison SJ; Lade S; Leslie C; Perram J; Prince HM; Radeski D; Rischmueller M; Wallington‐Gates C; Weber N; Hoi A, 2026, 'Author reply', Internal Medicine Journal, http://dx.doi.org/10.1111/imj.70641

Kurniawan S; Hwang A; Doo NW; King T; Bryant C; Zhang J; Whelan K; Fani-Molky P; Kidson-Gerber G; Bosco A; Hamad N; Parmar G; Kwok F; Lai S; Ling S; Ho PJ; McCaughan G; Bryant A, 2026, 'Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant-Ineligible Newly Diagnosed Myeloma: An Australian Real-World, Multicenter Study', Asia Pacific Journal of Clinical Oncology, 22, pp. 573 - 583, http://dx.doi.org/10.1111/ajco.70101

Lim KJC; Ashrafi E; Wellard C; Moore EM; Gration B; Augustson B; Mollee P; Zhang J; Doo NW; Dun K; Cooke R; Ringkowski S; Bryant A; McCaughan G; Wood E; McQuilten Z; Ho PJ; Quach H; Spencer A, 2026, 'Real-world application of the International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) consensus on genomic staging for high-risk multiple myeloma: A report from the Australia and New Zealand Myeloma and Related Diseases Registry', British Journal of Haematology, 209, pp. 764 - 768, http://dx.doi.org/10.1111/bjh.70609

Talaulikar D; Ng JY; Bryant A; Bosco A; Caterson HC; Giri P; Hissaria P; Harrison SJ; Lade S; Leslie C; Perram J; Prince HM; Radeski D; Rischmueller M; Wallington-Gates C; Weber N; Hoi A, 2026, 'Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease', Internal Medicine Journal, 56, pp. 1218 - 1239, http://dx.doi.org/10.1111/imj.70460

Rifkin R; Hungria V; Hus M; Zherebtsova V; Ward C; Ho PJ; Maiolino A; Hájek R; Kim K; Sia H; Bryant A; de Lacerda MP; Sureda A; Kazeem B; Baig H; Pirooz N; Varghese S; Lee J; Jiang T; Robak P; Mateos M-V; Abdallah A-O, 2026, 'MM-1168: Belantamab Mafodotin, Bortezomib, and Dexamethasone vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Updated 4-Year Results of the Phase 3 DREAMM-7 Trial', Clinical Lymphoma Myeloma & Leukemia, 26, pp. s1151 - s1152, http://dx.doi.org/10.1016/s2152-2650(26)02995-2

Rifkin R; Hungria V; Hus M; Zherebtsova V; Ward C; Ho PJ; Maiolino A; Hájek R; Kim K; Sia H; Bryant A; de Lacerda MP; Sureda A; Kazeem B; Baig H; Pirooz N; Varghese S; Lee J; Jiang T; Robak P; Mateos M-V; Abdallah A-O, 2026, 'POSTER: MM-1168: Belantamab Mafodotin, Bortezomib, and Dexamethasone vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Updated 4-Year Results of the Phase 3 DREAMM-7 Trial', Clinical Lymphoma Myeloma & Leukemia, 26, pp. s351, http://dx.doi.org/10.1016/s2152-2650(26)01419-9

Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho PJ; Hájek R; Kim K; Grosicki S; Sia H; Bryant A; Pitombeira de Lacerda M; Martinez GA; Sureda Balarí A; Sandhu I; Cerchione C; Ganly P; Dimopoulos MA; Fu C; Garg M; Abdallah AO; Gatt ME; Oriol Rocafiguera A; Cavo M; Rifkin R; Fujisaki T; Mielnik M; Ficek J; Mantero A; Pirooz N; Varghese S; Lee J; McKeown A; Rogers R; Baig H; Eccersley L; Roy-Ghanta S; Mukhopadhyay P; Nielsen J; Opalinska J; Mateos MV, 2025, 'Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial', Lancet Oncology, 26, pp. 1067 - 1080, http://dx.doi.org/10.1016/S1470-2045(25)00330-4

Bryant A; Quach H, 2024, 'Biomarker-directed therapy in multiple myeloma', Current Opinion in Oncology, 36, pp. 600 - 609, http://dx.doi.org/10.1097/CCO.0000000000001091

Li EW; Jones E; Bryant C; King T; Talaulikar D; Ng JY; Bryant A; Ridha Z; Doo NW; Menzies A; Ling S; Ho SJ; Abadir E; Vanguru V; Joshua D; Ho PJ, 2024, 'A single-day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies', European Journal of Haematology, 113, pp. 521 - 529, http://dx.doi.org/10.1111/ejh.14266

Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho PJ; Ribas de Almeida AC; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; Pitombeira de Lacerda M; Martinez GA; Balarí AMS; Sandhu I; Cerchione C; Ganly P; Dimopoulos M; Fu C; Garg M; Abdallah AO; Oriol A; Gatt ME; Cavo M; Rifkin R; Fujisaki T; Mielnik M; Pirooz N; McKeown A; McNamara S; Zhou X; Nichols M; Lewis E; Rogers R; Baig H; Eccersley L; Roy-Ghanta S; Opalinska J; Mateos MV, 2024, 'Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma', New England Journal of Medicine, 391, pp. 393 - 407, http://dx.doi.org/10.1056/NEJMoa2405090

Tong MH; Kwok A; Walsh A; Heydon P; Koh ES; McNamara N; Bryant A, 2024, 'Isolated Ocular Relapse of Acute Myeloid Leukaemia Post Allogeneic Stem Cell Transplant', Case Reports in Ophthalmological Medicine, 2024, http://dx.doi.org/10.1155/2024/2235819

Al‐Ammari M; Hsu D; Bryant A, 2024, 'Myeloma‐associated hemophagocytic lymphohistiocytosis – A comprehensive case study and a novel chemotherapy‐free approach with anakinra', eJHaem, 5, pp. 1057 - 1062, http://dx.doi.org/10.1002/jha2.975

Ponraj R; Bryant A; Dunlop L; Range H; Cobrador C; Ling S; Hsu D, 2023, 'Carfilzomib-induced thrombotic microangiopathy (TMA): an under-recognised spectrum of disease from microangiopathic haemolysis to subclinical TMA', Blood Cancer Journal, 13, pp. 113, http://dx.doi.org/10.1038/s41408-023-00885-9

Plesner T; Harrison SJ; Quach H; Lee C; Bryant A; Vangsted A; Estell J; Delforge M; Offner F; Twomey P; Choeurng V; Li J; Hendricks R; Ruppert SM; Sumiyoshi T; Miller K; Cho E; Schjesvold F, 2023, 'Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma', Clinical Hematology International, 5, pp. 43 - 51, http://dx.doi.org/10.1007/s44228-022-00023-5

McCaughan GJ; Verma A; Ling S; Lavee O; Moore JJ; Bryant A, 2021, 'Weekly cyclophosphamide, subcutaneous bortezomib and dexamethathasone (CyBorD) for initial treatment of transplant-eligible patients with multiple myeloma: experience of two transplant centres', Bone Marrow Transplantation, 56, pp. 738 - 740, http://dx.doi.org/10.1038/s41409-020-01086-9

Othman J; Greenwood M; Moore J; Larsen S; Watson AM; Arthur C; Bhattacharyya A; Bilmon I; Blyth E; Bryant A; Bryant C; Dunlop L; Fay K; Gibson J; Hamad N; Kerridge I; Kwan J; Ma D; Micklethwaite K; Milliken S; Panicker S; Stevenson W; Withers B; Wilcox L; Tran S; Gottlieb DJ, 2020, 'Unrelated Donor Transplant Recipients Given Thymoglobuline Have Superior GRFS When Compared to Matched Related Donor Recipients Undergoing Transplantation without ATG', Biology of Blood and Marrow Transplantation, 26, pp. 1868 - 1875, http://dx.doi.org/10.1016/j.bbmt.2020.06.030

Palma CA; Al Sheikha D; Lim TK; Bryant A; Vu TT; Jayaswal V; Ma DDF, 2014, 'MicroRNA-155 as an inducer of apoptosis and cell differentiation in Acute Myeloid Leukaemia', Molecular Cancer, 13, http://dx.doi.org/10.1186/1476-4598-13-79

Dalal BI; Al Mugairi A; Pi S; Lee SY; Khare NS; Pal J; Bryant A; Vakil AP; Lau S; Mourad YRA, 2014, 'Aberrant Expression of CD13 Identifies a Subgroup of Standard-Risk Adult Acute Lymphoblastic Leukemia With Inferior Survival', Clinical Lymphoma Myeloma & Leukemia, 14, pp. 239 - 244, http://dx.doi.org/10.1016/j.clml.2013.10.003

Bryant A; Nivison-Smith I; Pillai ES; Kennedy G; Kalff A; Ritchie D; George B; Hertzberg M; Patil S; Spencer A; Fay K; Cannell P; Berkahn L; Doocey R; Spearing R; Moore J, 2014, 'Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients', Bone Marrow Transplantation, 49, pp. 17 - 23, http://dx.doi.org/10.1038/bmt.2013.142

Bilmon I; Nivison-Smith I; Hertzberg M; Ritchie D; Greenwood M; Spencer A; Kennedy G; Bryant A; Moore J, 2014, 'Outcomes following second allogeneic haematopoietic transplants using fludarabine–melphalan conditioning', Bone Marrow Transplantation, 49, pp. 852 - 853, http://dx.doi.org/10.1038/bmt.2014.23

Bryant A; Palma CA; Jayaswal V; Yang YH; Lutherborrow MA; Ma DD, 2012, 'miR-10a is aberrantly overexpressed in Nucleophosmin1 mutated acute myeloid leukaemia and its suppression induces cell death', Molecular Cancer, 11, pp. 8, http://dx.doi.org/10.1186/1476-4598-11-8

Loi TH; Campain A; Bryant AJ; Molloy T; Lutherborrow MA; Turner J; Yang YH; Ma DD, 2011, 'Discriminating lymphomas and reactive lymphadenopathy in lymph node biopsies by gene expression profiling', BMC Medical Genomics, 4, pp. 1 - 10, http://www.biomedcentral.com/1755-8794/4/27

Lutherborrow MA; Bryant AJ; Jayaswal V; Agapiou DJ; Palma CA; Yang YH; Ma DD, 2011, 'Expression profiling of cytogenetically normal acute myeloid leukemia identifies MicroRNAs that target genes involved in monocytic differentiation', American Journal of Hematology, 86, pp. 2 - 11, http://dx.doi.org/10.1002/ajh.21864

Sasson SC; Smith S; Seddiki N; Zaunders J; Bryant AJ; Koelsch KK; Weatherall CJ; Munier CM; McGinley C; Yeung J; Mulligan S; Moore JJ; Cooper DA; Milliken ST; Kelleher AD, 2010, 'IL-7 receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers', Cytokine, 50, pp. 58 - 68

Bryant A; Lutherborrow MA; Ma DD, 2009, 'The clinicopathological relevance of microRNA in normal and malignant haematopoiesis', Pathology, 41, pp. 204 - 213

Bryant A; Milliken ST, 2008, 'Successful reduced-intensity conditioning allogeneic HSCT for HIV-related primary effusion lymphoma', Biology of Blood and Marrow Transplantation, 14, pp. 601 - 602, http://dx.doi.org/10.1016/j.bbmt.2008.01.010

Bryant A; Low J; Austin SA; Joseph JE, 2008, 'Timely diagnosis and management of heparin-induced thrombocytopenia in a frequent request, low incidence single centre using clinical 4T`s score and particle gel immunoassay', British Journal of Haematology, 143, pp. 721 - 726

Bryant A; Moore J, 2006, 'Rituximab and its potential for the treatment of rheumatoid arthritis', Therapeutics and Clinical Risk Management, 2, pp. 207 - 212, http://dx.doi.org/10.2147/tcrm.2006.2.2.207

Bryant A; Moore J, 2006, 'Rituximab and its potential for the treatment of rheumatoid arthritis', Therapeutics and Clinical Risk Management, 2, pp. 207 - 212, http://dx.doi.org/10.2147/tcrm.s22207

Conference Presentations

Sim S; Bryant A; Forsyth C; Motorna O; Brotchie J; Hocking J; Yong A; Chien N; Kerridge I; Lai HC; Solterbeck A; Traficante R; Jocic M; Quach H, 2025, 'Interim analysis of efficacy and safety for ALLG MM25 (Viber-M): A phase I b/II study of venetoclax, iberdomide and dexamethasone for patients in first or second relapse of multiple myeloma with t(11;14)', http://dx.doi.org/10.1182/blood-2025-249

Hungria V; Hus M; Zherebtsova V; Ward C; Ho PJ; Almeida ACD; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; Lacerda MPD; Garcia EG; Balari AS; Kazeem B; Pirooz N; Lee J; Baig H; Eccersley L; Robak P; Mateos M-V; Varghese S, 2025, 'DREAMM-7 Study of Belantamab Mafodotin plus Bortezomib (V) plus Dexamethasone (d) vs Daratumumab plus Vd in Relapsed/Refractory Multiple Myeloma: Efficacy in Patients by Subsequent Therapy'

Ringkowski S; Yong A; Wheeler M; Ling S; Low M; McQuilten Z; Moore E; Spearing R; Weber N; Wellard C; Quach H; Spencer A; Swaraj S; Trotman J; Bryant A, 2024, 'Co-occurrence of Obesity and Diabetes adversely impacts overall survival (OS) in Multiple Myeloma (MM) – an analysis from the Australian and New Zealand Myeloma & Related Disease Registry (ANZ MRDR)', presented at Blood, 2024, Brisbane, 27 October 2024 - 30 October 2024

Kurniawan S; Hwang A; Wong Doo N; King T; Bryant C; Zhang J; Whelan K; Fani-Mokly P; Kidson-Gerber G; Bosco A; Parmar G; Kwok F; Lai S; Ling S; Ho P; McCaughan G; Bryant A, 2024, 'Real-world, multi-centre review of outcomes utilising harmonised lenalidomide, bortezomib and dexamethasone (RVd) protocols in transplant- ineligible (TI) newly diagnosed multiple myeloma (NDMM)', presented at Blood 2024, Brisbane, Australia, 27 October 2024 - 30 October 2024

Conference Abstracts

Garg M; Kureeman MY; Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho PJ; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; de Lacerda MP; Aparecida-Martinez G; Sureda Balari A; Mielnik M; Nichols M; Mouro J; Khalaf Z; Baig H; Polinkovsky M; Pirooz N; Varghese S; Lee J; Eccersley L; Mateos M-V, 2026, 'DREAMM-7: Long-term responders with belantamab mafodotin (BVd) versus daratumumab (DVd) combinations in relapsed/refractory multiple myeloma', in BRITISH JOURNAL OF HAEMATOLOGY, WILEY, ENGLAND, Liverpool, Vol. 208, pp. S237 - S237, presented at 66th Annual Scientific Meeting of the British-Society-for-Hematology (BSH), ENGLAND, Liverpool, 19 April 2026 - 21 April 2026

Kwan G; Kwan T; Fernando S; Lee F; Lin M; Yun J; Bryant A; Ling S; Toong C, 2026, 'Comparative performance of Freelite and N-Latex serum free light chain assays across a multicentre New South Wales cohort', in Pathology, Elsevier, Vol. 58, pp. s67, http://dx.doi.org/10.1016/j.pathol.2026.01.293

Zhong S; Ashraf MA; Dhir V; Matta L; Bryant A; McEwan A; Watson A-M; Hua M; Ng S; Hsu D; Dunlop L; Hsu H; Sungala N; Motum P; Beaton B, 2026, 'Duffy-null-associated absolute neutrophil count (DANC): an audit from south-western Sydney evaluating the neutrophil lower reference range for patients with DANC', in Pathology, Elsevier, Vol. 58, pp. s64, http://dx.doi.org/10.1016/j.pathol.2026.01.282

Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho PJ; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; de Lacerda MP; Martinez G; Balarí AS; Mielnik M; Nichols M; Mouro J; Khalaf Z; Baig H; Polinkovsky M; Pirooz N; Varghese S; Lee J; Eccersley L; Mateos M-V, 2025, 'Long-term responders from the Phase 3 dreamm-7 study of belantamab mafodotin plus bortezomib and dexamethasone vs daratumumab plus bortezomib and dexamethasone in Relapsed/Refractory multiple myeloma', in Blood, American Society of Hematology, Vol. 146, pp. 2262, http://dx.doi.org/10.1182/blood-2025-2262

Mateos M-V; Robak P; Hus M; Zherebtsova V; Ward C; Ho PJ; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; de Lacerda MP; Martinez G; Balarí AS; Ma J; Ma Y; Nichols M; Mouro J; Khalaf Z; Baig H; Kazeem B; Pirooz N; Varghese S; Lee J; Eccersley L; Hungria V, 2025, 'Patients with Relapsed/Refractory multiple myeloma who achieved sustained minimal residual disease negativity in the dreamm-7 trial', in Blood, American Society of Hematology, Vol. 146, pp. 2265, http://dx.doi.org/10.1182/blood-2025-2265

Murali S; Bryant A; Hua M; Sungala N; Motum P; Getta B, 2025, 'EWALL for Elderly Ph- B-ALL: Insights from a South Western Sydney case series', in EWALL for Elderly Ph- B-ALL: Insights from a South Western Sydney case series, Perth, presented at Blood, Perth, 26 October 2025 - 29 October 2025

Ringkowski S; Gration B; McCaughan G; Talam S; King T; Ho P; Bosco A; Yong A; Naidoo S; Wong Doo N; Ling S; Bryant A, 2025, 'Selinexor therapy in multiple myeloma: Implementation of clinical recommendations on use of Selinexor in Australia and review of toxicity and response', in Selinexor therapy in multiple myeloma: Implementation of clinical recommendations on use of Selinexor in Australia and review of toxicity and response, Perth, Australia, presented at Blood, Perth, Australia, 26 October 2025 - 29 October 2025

Bryant A; Hungria V; Hus M; Zherebtsova V; Ward C; Ho PJ; Ribas de Almeida A; Hajek R; Kim K; Grosicki S; Sia H; Pitombeira de Lacerda M; Garcia E; Balarí A; Kazeem B; Baig H; Pirooz N; Varghese S; Lee J; Eccersley L; Robak P; Mateos M, 2025, 'DREAMM-7 study of belantamab mafodotin + bortezomib + dexamethasone (BVd) vs daratumumab + bortezomib + dexamethasone (DVd) in RRMM: efficacy in patients by subsequent therapy', in DREAMM-7 study of belantamab mafodotin + bortezomib + dexamethasone (BVd) vs daratumumab + bortezomib + dexamethasone (DVd) in RRMM: efficacy in patients by subsequent therapy, Perth, Australia, presented at Blood, Perth, Australia, 26 October 2025 - 29 May 2026

Khalaf Z; Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho P; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; de Lacerda M; Martinez G; Balari A; Sandhu I; Cerchione C; Ganly P; Dimopoulos M; Fu C; Garg M; Abdallah A-O; Gatt M; Oriol A; Cavo M; Rifkin R; Fujisaki T; Mielnik M; Pirooz N; Lee J; McKeown A; Rogers R; Baig H; Eccersley L; Roy-Ghanta S; Opalinska J; Mateos M, 2025, 'Belantamab Mafodotin plus Bortezomib plus Dexamethasone vs Daratumumab plus Vd in RRMM: Updates on Overall Survival and Efficacy in DREAMM-7', in BRITISH JOURNAL OF HAEMATOLOGY, WILEY, SCOTLAND, Glasgow, Vol. 206, presented at 65th Annual Scientific Meeting of the British-Society-for-Haematology, SCOTLAND, Glasgow, 27 April 2025 - 29 April 2025

Dimopoulos M; Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho P; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; Lacerda M; Martinez G; Balari A; Sandhu I; Cerchione C; Ganly P; Fu C; Garg M; Abdallah A-O; Gatt M; Oriol A; Cavo M; Rifkin R; Fujisaki T; Mielnik M; Pirooz N; Lee J; Mckeown A; Rogers R; Baig H; Eccersley L; Roy-Ghanta S; Opalinska J; Mateos M, 2025, 'BELANTAMAB MAFODOTIN plus BORTEZOMIB plus DEXAMETHASONE (BVD) VS DARATUMUMAB plus VD (DVD) IN RRMM: UPDATES ON OVERALL SURVIVAL (OS) AND EFFICACY IN DREAMM-7', in HAEMATOLOGICA, FERRATA STORTI FOUNDATION, GREECE, Athens, Vol. 110, pp. 41 - 41, presented at 6th European-Myeloma-Network Meeting, GREECE, Athens, 10 April 2025 - 12 April 2025

Hungria V; Hus M; Zherebtsova V; Ward C; Ho PJ; Almeida ACD; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; de Lacerda MP; Garcia EG; Balari AS; Kazeem B; Baig H; Pirooz N; Varghese S; Lee J; Eccersley L; Robak P; Mateos V, 2025, 'DREAMM-7 Study of Belantamab Mafodotin plus Bortezomib plus Dexamethasone vs Daratumumab plus Bortezomib plus Dexamethasone in Relapsed/ Refractory Multiple Myeloma: Efficacy in Patients by Subsequent Therapy', in CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, CIG MEDIA GROUP, LP, Vol. 25

Hungria V; Hus M; Zherebtsova V; Ward C; Ho PJ; de Almeida AC; Hájek R; Kim K; Grosicki S; Sia H; Bryant A; de Lacerda MP; Garcia EG; Balarí AS; Kazeem B; Pirooz N; Varghese S; Lee J; Baig H; Eccersley L; Robak P; Mateos M-V, 2025, 'PA-475 DREAMM-7 Study of Belantamab Mafodotin + Bortezomib (V) + Dexamethasone (d) vs Daratumumab + Vd in Relapsed/Refractory Multiple Myeloma: Efficacy in Patients by Subsequent Therapy', in Clinical Lymphoma Myeloma & Leukemia, Elsevier, Vol. 25, pp. s321 - s322, http://dx.doi.org/10.1016/s2152-2650(25)03938-2

Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho PJ; de Almeida AC; Hájek R; Kim K; Grosicki S; Sia H; Bryant A; de Lacerda MP; Aparecida-Martinez G; Balarí AS; Kazeem B; Lin CP; Baig H; Pirooz N; Varghese S; Lee J; Eccersley L; Khalaf Z; Mateos M-V, 2025, 'PA-494 Outcomes in Second-Line Lenalidomide-Refractory Patients in the Phase 3 DREAMM-7 Study of Belantamab Mafodotin, Bortezomib (V), and Dexamethasone (d) vs Daratumumab-Vd in RRMM', in Clinical Lymphoma Myeloma & Leukemia, Elsevier, Vol. 25, pp. s333 - s334, http://dx.doi.org/10.1016/s2152-2650(25)03957-6

Hungria V; Hus M; Zherebtsova V; Ward C; Ho PJ; de Almeida AC; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; de Lacerda MP; Garcia EG; Balarí AS; Kazeem B; Baig H; Pirooz N; Varghese S; Lee J; Eccersley L; Robak P; Mateos M-V, 2025, 'POSTER: MM-1049 DREAMM-7 Study of BelantamabMafodotin + Bortezomib + Dexamethasone vs Daratumumab + Bortezomib + Dexamethasone in Relapsed/Refractory Multiple Myeloma: Efficacy in Patients by Subsequent Therapy', in Clinical Lymphoma Myeloma & Leukemia, Elsevier, Vol. 25, pp. s306, http://dx.doi.org/10.1016/s2152-2650(25)01319-9

Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho PJ; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; Lacerda MPD; Martinez GA; Sureda Balarí AM; Sandhu I; Cerchione C; Ganly P; Dimopoulos M; Fu C; Garg M; Abdallah A-O; Gatt ME; Oriol A; Cavo M; Rifkin R; Fujisaki T; Mielnik M; Pirooz N; Lee J; McKeown A; Rogers R; Baig H; Eccersley L; Roy-Ghanta S; Mateos MV, 2024, 'Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial', in Blood, American Society of Hematology, Vol. 144, pp. 772 - 772, http://dx.doi.org/10.1182/blood-2024-200336

Lim KJC; Wellard C; Moore E; Gration B; Augustson B; Mollee P; Zhang J; Doo NW; Ringkowski S; Bryant A; Ninkovic S; Hamad N; McCaughan G; Kumar S; Spencer A; Quach H, 2024, 'Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry', in Blood, American Society of Hematology, Vol. 144, pp. 1951, http://dx.doi.org/10.1182/blood-2024-207609

Back to profile page